MeiraGTx Holdings plc

NASDAQ:MGTX

Biotechnology

Healthcare
$8.32 +5.08%

+$0.53 today

Market cap
$813.12M
Beta
1.26
P/E (TTM)
-7.4
EPS (TTM)
-$1.48
52W Low $6.07High $11.85

Volume 0.58M

Average 0.84M

MGTX Acquisitions (Net)

Cash paid for acquiring businesses, net of cash acquired.

MeiraGTx Holdings plcNASDAQ: MGTX

Acquisitions (Net) · Q1 FY2026 · quarter ended Mar 2026

Acquisitions (net) outflow grows to $0

Q1 FY2026 acquisitions (net) was $0, compared with $0 a year earlier. Trailing-twelve-month acquisitions (net) was $473K.

Context

  • Acquisitions (net) amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Acquisitions (net) increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly acquisitions (net) holds near $0 or moves back toward the trailing-twelve-month quarterly average of $118.25K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0-100.0% QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$473K— YoY
Acquisitions (Net) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Acquisitions (Net) history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
—

Acquisitions (Net) vs competitors

How MGTX compares with its peers on the latest reported figures

  • MGTX's LTM Mar 2026 acquisitions (net) of $473K is the 2nd largest of the 9 companies compared; the peer median is $0.
  • Acquisitions (net) amounts to 0.6% of revenue for MGTX, versus a peer median of 0.0%.
MGTX Competitors Peer median
Acquisitions (Net) for MGTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SANASana Biotechnology, Inc.LTM Mar 2026$1.02M +302.8%——
MGTXMeiraGTx Holdings plcLTM Mar 2026$473K ——0.6%
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026$11K ——0.0%
KRYSKrystal Biotech, Inc.LTM Jun 2026$0 ——0.0%
QUREuniQure N.V.LTM Mar 2026$0 ——0.0%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$0 ——0.0%
RGNXREGENXBIO Inc.LTM Mar 2026$0 ——0.0%
OCGNOcugen, Inc.LTM Mar 2026$0 ——0.0%
LCTXLineage Cell Therapeutics, Inc.LTM Mar 2026$0 ——0.0%
Peer median (excluding MGTX) $0+302.8%—0.0%

Competitors are the stored peer set for MGTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(79.56M)(129.62M)(84.03M)(147.79M)(114.2M)
Depreciation & Amortization7.87M8.6M13.72M12.68M12.7M
Deferred Income Tax00000
Stock-Based Compensation20.78M28.62M27.72M25.19M22.11M
Change in Working Capital31.28M9.62M(983K)29.64M28.03M
Accounts Receivables16.7M5.17M4.83M9.43M(7.27M)
Inventory000(387K)428K
Accounts Payables13.35M3.74M2.33M10.74M(12.31M)
Other Working Capital1.23M713K(8.14M)9.87M47.18M
Other Non-Cash Items9.1M9.67M(61.8M)(24.22M)5.01M
Operating Cash Flow(10.53M)(73.1M)(105.37M)(104.5M)(46.36M)
Capital Expenditures(55.22M)(44.96M)(20.17M)(4.96M)(3.83M)
Acquisitions (Net)(6.5M)0000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities0054.21M28.43M(281K)
Investing Cash Flow(61.72M)(44.96M)34.03M23.48M(4.11M)
Debt Repayment(1K)75M00(29K)
Common Stock Issued1.71M25M91.95M59.39M15.33M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities0(4.8M)(7.93M)(4.86M)(3.03M)
Financing Cash Flow1.71M95.2M84.02M54.53M12.27M
Effect of Forex Changes(1.28M)674K2.44M1.5M719K
Net Change in Cash(71.82M)(22.19M)15.13M(24.98M)(37.48M)
Free Cash Flow(65.75M)(118.06M)(125.54M)(109.45M)(50.19M)

MeiraGTx Holdings plc

NASDAQ:MGTX

Intrinsic Alpha fair value

Locked

Current Price

$8.32

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.